Form D · Other
BioLoomics, Inc.
Boulder, CO · CIK 0001776021
Offering snapshot reported Nov 10, 2025 · SEC filing
- Reported sold
- $450K Offering amount: $2M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 11, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 10, 2025 | Initial | $450,000 | No comparison | 5 | SEC filing |
| Mar 13, 2023 | Initial | $9,349,939 | No comparison | 23 | SEC filing |
| May 17, 2021 | Initial | $575,000 | No comparison | Not reported | SEC filing |
| Jun 10, 2019 | Initial | $600,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-563596
Source: Form D, filed Nov 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas A Chapnick | Director, Executive, Promoter |
| Joel Dudley | Director |
| Nicholas Saccomano | Director |
Issuer details
Industry: Other (See others in industry)
Address:
85 Forrest Lane
Boulder, CO, 80302
Boulder, CO, 80302